Biochemist Joanne Lemieux worked with three other U of A researchers on a new study showing that a drug that cures deadly peritonitis in cats also works well enough against the coronavirus that causes COVID-19 to fast-track it into human clinical trials. (Photo: Supplied)
Fast-tracked research leads to phase 1 clinical trials.
Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect will also be effective as a treatment for humans against COVID-19.
“In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2,” said Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry.
“This drug is very likely to work in humans, so we’re encouraged that it will be an effective antiviral treatment for COVID-19 patients.”
The drug is a protease inhibitor that interferes with the virus’s ability to replicate, thus ending an infection. Proteases are key to many body functions and are common targets for drugs to treat everything from high blood pressure to cancer and HIV.
First studied by U of A chemist John Vederas and biochemist Michael James following the 2003 outbreak of severe acute respiratory syndrome (SARS), the protease inhibitor was further developed by veterinary researchers who showed it cures a disease that is fatal in cats.
The work to test the drug against the coronavirus that causes COVID-19 was a co-operative effort between four U of A laboratories, run by Lemieux, Vederas, biochemistry professor Howard Young and the founding director of the Li Ka Shing Institute of Virology, Lorne Tyrrell. Some of the experiments were carried out by the Stanford Synchrotron Radiation Lightsource Structural Molecular Biology program.
“There’s a rule with COVID research that all results need to be made public immediately,” Lemieux said, which is why they were posted before being peer-reviewed.
She said interest in the work is high, with the paper being accessed thousands of times as soon as it was posted.
Lemieux explained that Vederas synthesized the compounds, and Tyrrell tested them against the SARS-CoV-2 virus in test tubes and in human cell lines. The Young and Lemieux groups then revealed the crystal structure of the drug as it binds with the protein.
”We determined the three-dimensional shape of the protease with the drug in the active site pocket, showing the mechanism of inhibition,” she said. “This will allow us to develop even more effective drugs.”
Lemieux said she will continue to test modifications of the inhibitor to make it an even better fit inside the virus.
But she said the current drug shows enough antiviral action against SARS-CoV-2 to proceed immediately to clinical trials.
“Typically for a drug to go into clinical trials, it has to be confirmed in the lab and then tested in animal models,” Lemieux said. “Because this drug has already been used to treat cats with coronavirus, and it’s effective with little to no toxicity, it’s already passed those stages and this allows us to move forward.”
“Because of the strong data that we and others have gathered we’re pursuing clinical trials for this drug as an antiviral for COVID-19.”
The researchers have established a collaboration with Anivive Life Sciences, a veterinary medicine company that is developing the drug for cats, to produce the quality and quantity of drug needed for human clinical trials. Lemieux said it will likely be tested in Alberta in combination with other promising antivirals such as remdesivir, the first treatment approved for conditional use in some countries including the United States and Canada.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Study reveals potential utility of artemisinin-based treatments against SARS-CoV-2on October 6, 2020 at 5:22 pm
In a recent, methodologically robust bioRXiv preprint paper, researchers from Germany, Denmark and Hong Kong report in vitro efficacy of extracts from the sweet wormwood plant (Artemisia annua), but ...
- New research supports sofosbuvir in combination with other antivirals for COVID-19on October 6, 2020 at 11:01 am
Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results ...
- New research supports sofosbuvir in combination with other antivirals for COVID-19 (TDnews)on October 6, 2020 at 9:36 am
This figure shows that there is substantially more cleavage of Remdesivir-RNA (g, h, i) than Sofosbuvir-RNA (a, b, c) by SARS-CoV-2 exonuclease. It is also apparent that Remdesivir-RNA (g, h,… view ...
- Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIVon October 6, 2020 at 4:30 am
PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of ...
- Approved MS medication inhibits SARS-CoV-2 replication in vitroon October 5, 2020 at 5:14 am
Dimethyl fumarate (DMF), a multiple sclerosis (MS) drug, inhibited SARS-CoV-2 replication and the COVID-19 hyper-inflammatory response.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Opinion: Is the COVID-19 cure worse than the disease? The most polarising question of 2020on October 6, 2020 at 4:11 pm
Instead, they called for a "targeted and evidence-based approach to the COVID-19 policy response". A week later, science writer Stephen Buranyi wrote a piece for the Guardian arguing that the ...
- Trump’s COVID-19 Misinformation Since Testing Positiveon October 6, 2020 at 3:45 pm
Even after contracting the coronavirus and being hospitalized, President Donald Trump has continued to downplay the risks of COVID-19 and exaggerate the progress the U.S. has made in fighting the ...
- Kim Kardashian explains ‘scary’ experience when Kanye West had COVID-19on October 6, 2020 at 2:40 pm
West recently explained what it was like to treat Kanye West when he was first infected with COVID-19 at the beginning of the pandemic. She told GRAZIA that Kanye West became diagnosed in mid-March ...
- Gov. DeSantis’s hand-picked ‘experts’ can’t change reality of COVID-19 | Randy Schultzon October 6, 2020 at 12:17 pm
When the science doesn’t align with DeSantis, he tries to change the science. On Sept. 25, DeSantis surprised counties and cities by moving the state into Phase 3 of reopening. The three-page order ...
- 'We're relying on science to save us': Katy infectious disease experts discuss COVID-19 vaccineon October 6, 2020 at 11:44 am
The COVID-19 pandemic has claimed the lives of more than 200,000 Americans, and according to infectious disease experts, no miracle cure is coming. Herd immunity, the worst-case scenario ending to the ...